This new license agreement provides the rights for the Company’s development and sale of cannabinoid(s) and cannabidiol(s) based therapeutics as antioxidants and neuroprotectants for use and delivery in
At the conclusion of the inspection, the FDA issued a Form 483 with seven inspectional observations, two of which are designated as repeat observations. The FDA did not
The company is working with GlaxoSmithKline to ensure sufficient supply to meet anticipated demand. The company and its lenders are also performing additional due diligence related to this
By joining The US Oncology Network, the physicians at Optim Oncology and Urology Centers of Oklahoma can collaborate with other oncology experts from across the nation in real
RXDX-103 is an inhibitor of the cell division cycle 7-related (Cdc7) protein kinase, and RXDX-104 is a program to identify a highly selective inhibitor of the rearranged during
In exchange for a one-time, upfront payment of $5.0 million, Infinity receives an option to terminate its obligation to pay Millennium future royalties related to the sale of
The acquisition will include the Intellectual Properties ("IP"), assets and talents of this cancer-therapy-focused developmental stage company. The IP is comprised of T Cells Receptor ("TCR") clonality analysis
The approval of this indication is now consistent with that of the rest of the world, where alglucosidase alfa manufactured at the 4000L is the only scale available.
Esperante is the investment arm of the C&P Group, a global, privately owned group of life science businesses including Nordic Pharma, a fully-integrated, pan-European pharmaceutical and services company,
Dr. James Andrews, the legendary orthopedic surgeon will be the principal investigator for the study. inVentiv Health Clinical will serve as the Clinical Research Organization (CRO) for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.